

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: JORGENSEN, K. et al. Conf.: N/A
Appl. No.: NEW Group: 1615
Filed: February 26, 2004 Examiner: KISHORE, G.
For: LIPID-BASED MICROCARRIER DRUG-DELIVERY
SYSTEM CONTAINING PHOSPHOLIPASE A₂
DEGRADABLE LIPID AGENTS AND THE
THERAPEUTIC USES THEREOF

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

February 26, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).

09/781,893

U.S. Filing Date(s)

February 9, 2001

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #46,183
Leonard R. Svensson, #30,330

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

LRS/KR/sml
2081-0125P

Attachment(s): ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 09/30/03)

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	ATTY DOCKET NO. 2081-0125P	APPLICATION NO. Unknown
	APPLICANT Kent JORGENSEN, et al.	
	FILING DATE February	GROUP 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	5	8	2	7	8	3	6	1998-10-27	Peterson, et al.			
	5	4	8	4	9	1	1	1996-01-16	Hong, et al.			
	4	6	2	2	3	9	2	1986-11-11	Hong, et al.			
	5	9	4	2	2	4	6	1999-08-24	Mayhew, et al.			
	5	9	3	2	2	4	2	1999-08-03	Franklin, et al.			
	6	9	6	5	1	5	9	1999-10-12	Mayhew, et al.			
	6	0	0	7	0	3	9	1999-12-28	Mayhew, et al.			
	5	0	8	2	6	7	9	1999-03-16	Needham			
	5	9	8	5	0	5	6	1999-11-16	Kozak			
	6	0	7	7	8	3	7	2000-06-20	Kozak			
	6	1	3	6	7	9	6	2000-10-24	Kozak			
	6	1	6	6	0	8	9	2000-12-26	Kozak			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
												YES	NO
	ES	2	0	3	4	8	84	1994-03-01	SPAIN				
	WO 94	0	9	0	1	4		1994-04-28	PCT				
	WO 94	2	2	4	8	3		1994-10-13	PCT				
	WO 99	0	2	1	2	0		1999-01-21	PCT				
	WO 99	0	2	4	0	5		1999-01-21	PCT				
	WO 99	1	6	7	4	1		1999-04-08	PCT				

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

	"Therapeutic Activity of a Thioether-Lipid Conjugate of 1- β -D-Arabinofuranosylcytosine in Human Colorectal Cancer Xenografts", R. Herrmann, et al, Am. Assoc. Cancer Res., Vol. 52, No. 7, pp. 1865-1867 (1992)
	"Competitive Inhibition of Lipolytic Enzymes. IX. A comparative Study on the Inhibition of Pancreatic Phospholipases A ₂ from Different Sources by (R)-2-acylamino Phospholipid Analogues", G. H. de Haas, et al, BBA - Lipids and Lipid Metabolism, NL, Elsevier Science BV., Vol. 1167, No. 3, 1993, pp. 281-288
	"The Chemical Synthesis of a Series of Ether Phospholipids From D-Mannitol and Their Properties", J Xia, et al, Tetrahedron: Asymmetry, Vol. 8, No. 18, pp. 3131-3142, 1997

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LRS/KR/sml

Form PTO-1449					ATTY DOCKET NO. 2081-0125P					APPLICATION NO. Unknown									
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)										APPLICANT Kent JORGENSEN, et al.									
										FILING DATE February					GROUP 1615				
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER						DATE		NAME				CLASS		SUB CLASS		FILING DATE IF APPROPRIATE	
		5 8 5 9 2 2 8						1999-01-12		JANJIC et al.									
		6 2 2 9 0 0 2						2001-05-08		JANJIC et al.									
FOREIGN PATENT DOCUMENTS																			
		DOCUMENT NUMBER						DATE		COUNTRY				CLASS		SUB CLASS		TRANSLATION	
																		YES NO	
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.																			
		"Cytotoxicity of Platelet Activating Factor and Related Alkyl-Phospholipid Analogs in Human Leukemia Cells, Polymorphonuclear Neutrophils, and Skin Fibroblasts", D. Hoffman, et al, Blood, Vol. 63, No. 3, 1984, pp. 545-552																	
		Enzymatic Degradation of Polymer Covered SOPC-Liposomes in Relation to Drug Delivery", J. Davidsen, et al, Symposium on Lipid and Surfactant Self-Assemblies: Structure, Dynamics and Reactions, Feb. 24-25, 2000, Uppsala, Sweden																	
		"Controlled Destabilization of Liposomal Drug Delivery Systems by Phospholipase A ₂ ", J Davidsen, et al, Dec. 1999																	
		"Increased Cell-surface Receptor Expression on U-937 Cells Induced by 1-0-octadecyl-2-0-methyl-sn-glycero-3-phosphocholine", M. Pushkareva, et al, Cancer Immunol Immunother (2000) 48: 569-578																	
		"Ether Lipids in the Therapy of Cancer", R. Andreesen, Prog. Biochem, Pharmacol, Vol 22, pp. 118-131 1988																	
		"1-β-D-Arabinofuranosylcytosine-Phospholipid Conjugates As Prodrugs of Ara-C", C. Hong, et al, Cancer Drug Delivery, Vol. 1, No. 3, 1984, pp. 181-190																	
		"Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Conjugates of Ether Lipids", C. Hong, et al, J. Med. Chem. 1986, 29, 2038-2044																	
		"Phospholipid Antitumor Agents", W. Houlihan, et al., Medicinal Research Reviews, Vol. 15, No. 3, 157-223 (1995)																	
		"Antitumor Ether Lipids and Alkylphosphocholines", M. Lohmeyer, et al, Drugs of the Future, 1994, 19(11): 1021-1037																	
		"Growth Arrest vs. Direct Cytotoxicity and the Importance of Molecular Structure for the In vitro Anti-Tumor Activity of Ether Lipids", M. Lohmeyer, et al, British Journal of Cancer (1995) 72, pp. 277-286																	
		"Enhancement of Phospholipase A ₂ Catalyzed Degradation of Polymer Grafted PEG-Liposomes: Effects of Lipopolymer-concentration and Chain-Length", K Jorgensen, et al., Pharmaceutical Research, Vol. 16, No. 9, 1999 pp. 1491-1493																	
		"Increase in Phospholipase A ₂ Activity Towards Lipopolymer-Containing Liposomes, C. Vermehren, et al, BBA, 1998, pp.27-36																	
EXAMINER										DATE CONSIDERED									
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																			